HLA Pattern Determination for Tailored Cancer Therapy
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current cancer treatments are often ineffective and accompanied by severe side effects due to their non-targeted approach, as they do not account for the unique HLA patterns of individual tumor cells, leading to inadequate immune response and uncontrolled tumor growth.
Innovation Solution
An in vitro method for determining individual HLA patterns in cancer patients using RNA transcript expression levels of HLA genes, allowing for tailored treatment stratification and the development of therapeutic agents that target specific HLA patterns.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If general non-targeted cancer therapy is applied to detect all rapidly dividing cells, then the therapy covers all potential tumor cells, but the treatment effectiveness decreases and severe side effects occur due to lack of individualization
Solution Approach 1:
The patent segments the general cancer therapy approach into individualized treatments by dividing patients into distinct groups based on their unique HLA patterns. Instead of applying a uniform therapy to all patients, the method separates the patient population into subsets with specific HLA characteristics, allowing tailored therapeutic strategies for each segment, thereby improving effectiveness while reducing unnecessary side effects on non-targeted cells
Solution Approach 2:
The patent applies local quality by customizing treatment properties according to the specific HLA pattern of each patient or patient group. The therapy characteristics (such as immune cell selection, cytokine therapy, or vaccine composition) are locally adapted to match the individual's HLA profile, ensuring that the treatment quality is optimized for each specific case rather than applying a one-size-fits-all approach
2Measurement precision
If individualized therapy based on HLA patterns is implemented, then treatment precision and effectiveness improve, but the complexity of diagnosis and treatment planning increases
Solution Approach 1:
The patent employs universal HLA pattern classification categories that can be applied across different cancer types and patient populations. By establishing universal HLA groups (such as HLA-A2, HLA-B7, HLA-Cw3 associations with specific tumor types), the system achieves high measurement precision while maintaining diagnostic framework simplicity, as the same classification approach works universally across various malignancies
Solution Approach 2:
The patent simplifies the complex HLA system by focusing on specific HLA gene parameters (A, B, C, D, E, F, G) and their expression patterns rather than analyzing the entire HLA complex. This parameter selection approach reduces diagnostic complexity while maintaining sufficient precision for clinical decision-making, as these specific parameters are sufficient to generate meaningful individualized treatment profiles
3Productivity
If conventional chemotherapy targeting all rapidly dividing cells is used, then the treatment process is simple and rapid, but the loss of healthy cells increases and treatment specificity decreases
Solution Approach 1:
The patent introduces HLA pattern analysis as an intermediary step between diagnosis and treatment. This intermediary classification system enables rapid patient stratification into HLA-specific groups, allowing the treatment process to proceed quickly while directing therapy only at tumor cells with matching HLA patterns. This mediator approach maintains treatment speed by using simple HLA typing while preventing healthy cell loss through targeted immune cell or cytokine therapy selection
Data Source
AI summary
The present disclosure relates to in vitro methods of determining the individual HLA patterns (adult and/or embryonic) in body samples (tissue or blood samples) of cancer patients and/or patients suffering disorders related to autoimmune disease and to methods of stratifying said patients for tailored treatments. It further relates to corresponding kits and their uses, as well as to nucleic acid molecules as prognostic biomarkers for neoplastic disease such as cancer, autoimmune disease, infectious disease and conditions related to pregnancy. It also relates to therapeutic agents and to methods of producing therapeutic agents.